Nicole Sweeny Sells 1,861 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,861 shares of KalVista Pharmaceuticals stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $26.78, for a total value of $49,837.58. Following the completion of the sale, the insider directly owned 55,780 shares of the company’s stock, valued at $1,493,788.40. The trade was a 3.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Tuesday, May 26th, Nicole Sweeny sold 1,489 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $26.78, for a total value of $39,875.42.
• On Friday, April 17th, Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $20.22, for a total value of $37,649.64.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $26.79 on Thursday. The business has a fifty day moving average of $21.94 and a 200 day moving average of $17.65. KalVista Pharmaceuticals, Inc. has a one year low of $9.83 and a one year high of $26.85. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. The firm has a market capitalization of $1.43 billion, a P/E ratio of -7.74 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to analysts’ expectations of $39.03 million. As a group, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its stake in KalVista Pharmaceuticals by 45.8% during the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 589 shares during the period. Royal Bank of Canada raised its stake in KalVista Pharmaceuticals by 137.0% during the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock worth $59,000 after acquiring an additional 1,686 shares during the period. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $55,000. Finally, Truvestments Capital LLC raised its stake in KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 3,360 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Needham & Company LLC cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 30th. Leerink Partners cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Stifel Nicolaus increased their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. JonesTrading cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, KalVista Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $30.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.